Why We Age — The Biology of Getting Old

Aging feels universal and inevitable — but biologically, it isn't. Turritopsis dohrnii, the so-called "immortal jellyfish," can revert to its polyp stage when stressed and start its life cycle over indefinitely. Hydra show negligible senescence — their mortality rate barely rises with age. Naked mole rats live 30+ years, roughly ten times longer than similarly sized rodents, and rarely develop cancer. Some bristlecone pines are over 5,000 years old and still reproducing.

So the question "why do we age?" is genuinely open, and a serious branch of biology is now asking whether aging itself can be treated as a modifiable condition.

What Aging Actually Is

In 2013, López-Otín and colleagues published an influential paper in Cell defining the Hallmarks of Aging — a framework that has become the standard map of the field. The original paper listed 9 hallmarks; the 2023 update expanded it to 12.

The 12 hallmarks (2023):

1. Genomic instability — DNA damage accumulates faster than repair
2. Telomere attrition — protective caps on chromosomes shorten with each cell division
3. Epigenetic alterations — chemical marks on DNA drift, gene expression becomes dysregulated
4. Loss of proteostasis — misfolded proteins accumulate (Alzheimer's, Parkinson's)
5. Disabled macroautophagy — cellular "recycling" breaks down
6. Deregulated nutrient sensing — insulin/IGF-1, mTOR, AMPK, sirtuin pathways go awry
7. Mitochondrial dysfunction — the cell's power plants degrade
8. Cellular senescence — damaged cells stop dividing but don't die, secreting inflammatory signals (SASP)
9. Stem cell exhaustion — tissue regeneration declines
10. Altered intercellular communication — hormones and signaling drift
11. Chronic inflammation ("inflammaging")
12. Dysbiosis — gut microbiome composition shifts

These aren't independent causes — they interact. Senescent cells trigger inflammation, which damages DNA, which triggers more senescence, and so on.

Why Does Evolution Allow Aging?

If aging is so bad, why didn't natural selection eliminate it? Three classical theories, all probably partly true:

Free radical theory (Denham Harman, 1956): Reactive oxygen species (ROS) damage cellular components over time. Partially validated — oxidative stress is real — but antioxidant supplements have largely failed in clinical trials, suggesting it's more complicated.

Antagonistic pleiotropy (George Williams, 1957): Some genes boost fitness early in life (better growth, reproduction, immunity) but cause harm later. Selection favors them because evolution "cares" about reproductive success, not lifespan. Example: high testosterone aids reproduction but raises later prostate cancer risk.

Disposable soma (Tom Kirkwood, 1977): Organisms allocate finite energy between reproduction and somatic maintenance. Because predators, accidents, and disease would kill you eventually anyway, evolution under-invests in repair beyond reproductive age.

The common thread: selection pressure drops off after reproduction. A gene that makes you sick at 70 barely affects how many grandchildren you leave behind, so it doesn't get weeded out.

Interventions: What Has Evidence?

The longevity field is full of hype. Here's the honest evidence map.

Caloric restriction (CR)

The most robust life-extension intervention across species. ~30% calorie reduction (with adequate nutrition) extends lifespan in yeast, worms, flies, mice, and rats. In rhesus monkeys, two long-running studies (NIA and Wisconsin) disagreed — Wisconsin showed clear extension, NIA showed mixed results. In humans, the CALERIE trial showed metabolic and inflammatory benefits but couldn't measure lifespan in 2 years.

Rapamycin

An mTOR inhibitor originally developed as an immunosuppressant. The most reliable pharmaceutical life-extender in mice — extends median lifespan ~10-15% even when started late in life. Side effects (immune suppression, mouth sores, metabolic effects) make human dosing tricky. Off-label use is growing but quality evidence in humans is limited.

Senolytics

Drugs that kill senescent cells. The combination dasatinib + quercetin (D+Q) has shown promise in mouse models and small human trials for diseases like idiopathic pulmonary fibrosis. Fisetin is another candidate. Still early — clinical efficacy for healthy aging is unproven.

NAD+ boosters (NR, NMN)

Nicotinamide riboside and nicotinamide mononucleotide raise NAD+ levels, which decline with age. Supplements are popular but human evidence for actual longevity or healthspan benefits remains weak as of 2026.

Metformin

The cheap diabetes drug, possibly anti-aging through AMPK activation. The TAME trial (Targeting Aging with Metformin) led by Nir Barzilai is the first FDA trial designed to evaluate aging itself as an endpoint. Results still pending in 2026.

GLP-1 agonists (semaglutide, tirzepatide)

The blockbuster weight-loss drugs are turning out to reduce cardiovascular events, kidney disease, and possibly dementia risk — likely with significant healthspan implications, though "anti-aging" framing is speculative.

Partial reprogramming (Yamanaka factors)

Shinya Yamanaka won the Nobel for showing that four genes (OCT4, SOX2, KLF4, c-MYC) can revert adult cells to pluripotent stem cells. Cyclically expressing these factors partially in mice has reversed some aging markers without turning cells back to stem cells. Companies like Altos Labs (~$3B funding, Bezos-backed) and Calico (Google/Alphabet) are pursuing this. Cancer risk is the major concern.

Comparison: Aging Interventions by Evidence Level

Intervention	Evidence in animals	Evidence in humans	Risk profile	2026 status
Exercise	Strong	Strong	Very low	Proven
Sleep / no smoking / Mediterranean diet	Strong	Strong	None	Proven basics
Caloric restriction	Strong (most species)	Moderate (CALERIE)	Quality of life cost	Established benefit
Rapamycin	Strong (mice)	Limited	Immune suppression	Off-label / research
Metformin	Moderate	Awaiting TAME	Low	In trials
Senolytics (D+Q)	Strong (mice)	Early	Medium	Experimental
NAD+ boosters	Mixed	Weak	Low	Hype > evidence
GLP-1 agonists	N/A	Strong (healthspan)	Manageable	Approved for related uses
Partial reprogramming	Promising	None	Cancer risk	Pre-clinical
Most supplements	Mixed	Weak/none	Variable	Largely unproven

Notice the boring truth: the best-evidenced interventions are still exercise, sleep, diet, not smoking — things humans have known about for decades. For more on the cellular machinery involved, see our pieces on epigenetics and how telomeres shorten with age.

Deep Dive: Senescent Cells and Cellular Aging

One of the most actionable hallmarks is cellular senescence. When a cell detects irreversible damage (telomere shortening, DNA breaks, oxidative stress beyond repair), it can enter a state called "senescence" — it stops dividing but doesn't die. Instead, it secretes pro-inflammatory signals (the SASP, or senescence-associated secretory phenotype), triggering low-grade inflammation in surrounding tissues.

Why this matters: A single senescent cell doesn't seem like a problem. But in aging tissues, senescent cells accumulate dramatically — sometimes 1–2% of all cells in an aged organ are senescent. These cells:

• Promote tumor formation by creating a pro-inflammatory microenvironment
• Trigger senescence in neighboring cells (a spreading effect)
• Reduce tissue regeneration by suppressing stem cells
• Drive diseases like osteoarthritis, atherosclerosis, and neurodegeneration

The senolytics approach: Senolytics are drugs designed to selectively kill senescent cells while leaving healthy cells alone. The discovery by James Kirkland's lab at the Mayo Clinic showed that the combination dasatinib (a leukemia drug) + quercetin (a plant flavonoid) kills senescent cells in culture and extends healthspan in aging mice.

In humans, a 2022 trial in patients with diabetic kidney disease showed that a different senolytic, fisetin, reduced SASP markers in blood after 12 weeks. Whether this translates to actual disease prevention or extended lifespan in humans remains unknown, but senolytics are the most actionable near-term strategy emerging from aging research.

Source: Kirkland, J.L., Tchkonia, T. (2017). "Cellular Senescence: A Translational Perspective." EBioMedicine, 21: 21–28. — Foundational review on senolytics.

Recent Breakthroughs (2023–2026)

Senolytic combination therapy: Multiple compounds beyond D+Q are showing promise. Fisetin, piperlongumine, and ABT-263 (navitoclax) all kill senescent cells in mice with minimal off-target effects. Clinical trials are ramping up in 2026.

Epigenetic clock reversal: Steve Horwath's epigenetic clocks (biological age markers based on DNA methylation) showed that partial reprogramming factors (Yamanaka factors expressed cyclically) can reverse biological age in fibroblasts by ~2–3 years per cell. Whether this works in vivo at the whole-organism level is the next critical test.

Combination approaches: The longevity field is shifting from single-drug interventions to combinations — e.g., metformin + exercise, or rapamycin + senolytic. Synergistic effects may accelerate progress.

Microbiome engineering: Fecal microbiota transplantation and engineered probiotics designed to restore youthful microbial profiles have extended lifespan in mice. Human trials are beginning in aged populations.

Why Aging Remains Poorly Understood

Despite the "12 hallmarks" framework, aging is still largely a black box. The biggest unknowns:

1. Causation vs. correlation: Are the hallmarks causes of aging, or consequences? Fixing one (e.g., telomere shortening) doesn't necessarily fix aging.
2. Integration: How do the hallmarks interact? Models of aging are still mostly linear; real aging is deeply networked.
3. Individual variation: Some 80-year-olds have the cells of 50-year-olds; others vice versa. We don't understand the genetic and environmental factors that drive this.
4. Species differences: Caloric restriction extends lifespan in mice but effects in primates are unclear. Rapamycin works in mice but extrapolating to humans is speculative.

Despite decades of research, aging is still not preventable or reversible in humans. Our understanding is best understood as "early." Future breakthroughs will likely come from:

• Single-cell atlases revealing age-related cell type changes
• AI models integrating multi-omics (genomics, proteomics, metabolomics)
• Large randomized trials of interventions (TAME, etc.) now underway
• Regenerative medicine approaches (stem cell therapy, tissue engineering)

Frequently Asked Questions

Q: Will humans live to 150 in this century?
A: Possible but not predicted by expert opinion. Current maximum verified human lifespan is ~122 years (Jeanne Calment, 1997). This record hasn't been broken in 30 years despite population growth. Average lifespan in wealthy countries continues to rise (~83 years in Japan, the highest), but recent gains have slowed or reversed in some populations (US life expectancy has declined in recent years). Getting from average 85 to 150 would require not just incremental improvements but breakthroughs in multiple aging hallmarks simultaneously.

Q: Are blue zones real?
A: The geographic clusters are real, but claims about extraordinary longevity are overstated. Researcher Saul Newman (2024) showed that many "supercentenarian" claims worldwide result from poor record-keeping, pension fraud, and confusion with younger relatives. The authentic "Blue Zones" (Okinawa, Sardinia, Nicoya, Ikaria, Loma Linda) do have higher centenarian rates than global average, but not mysteriously so. Lifestyle factors (Mediterranean diet, strong community ties, regular physical activity, low stress) plausibly explain the difference.

Q: Is aging a disease that can be "cured"?
A: Highly debated. The WHO added an aging-related code (XT9T) to ICD-11 but didn't classify aging itself as a disease. Many gerontologists argue that treating aging as a disease would unlock faster regulatory pathways for therapies (like TAME trials). Others worry it pathologizes a normal process. Pragmatically, if we develop therapies that extend healthy lifespan and prevent age-related diseases, the semantic debate becomes moot.

Q: Does sunscreen really slow facial aging?
A: Yes — this is among the most evidence-based anti-aging interventions. UV radiation damages collagen and elastin, triggering the inflammatory cascade of photoaging. SPF 30+ daily sunscreen use reduces skin cancer risk by ~40% and visible photoaging (wrinkles, age spots) by ~50% in prospective trials. This is stronger evidence than most longevity supplements.

Q: Do telomeres completely explain aging?
A: No. Telomeres are one of the 12 hallmarks, not the driver of aging. Telomerase activation extends mouse lifespan in some models but increases cancer risk — cancer cells reactivate telomerase precisely to achieve immortality. Some organisms (like hydra) show negligible telomere shortening yet don't age noticeably. Telomeres matter, but they're not the full story.

Q: What single intervention has the strongest evidence for lifespan extension in humans?
A: Physical activity (exercise) shows the most robust evidence. Multiple large prospective studies and meta-analyses show regular aerobic and resistance exercise correlates with ~20–30% lower all-cause mortality and ~5–10 year longer healthspan. No pharmaceutical currently rivals this effect size. Walking 30+ minutes daily and resistance training 2x/week is the closest thing to a validated "anti-aging intervention" we have.

Organ-Specific Aging: How Tissues Decline at Different Rates

Aging is not uniform across the body. Different tissues accumulate hallmarks at different rates, explaining why some 70-year-olds have 40-year-old hearts while others have 90-year-old brains.

Brain aging: The brain loses roughly 5% of volume by age 80, particularly in the prefrontal cortex and hippocampus. Tau protein tangles and amyloid plaques accumulate (the hallmark of Alzheimer's). Dopamine and acetylcholine production decline, impacting cognition and movement. However, recent research shows that cognitive decline is not inevitable — people with high cognitive reserve (education, active thinking, bilingualism) maintain sharper cognition despite comparable amyloid load. The AARP study found that 10% of people over 80 show no cognitive impairment, suggesting plasticity persists late in life. Brain aging is influenced heavily by cardiovascular health, sleep quality, and physical activity.

Source: Stern, Y. (2012) "Cognitive Reserve in Ageing and Alzheimer's Disease," The Lancet Neurology, Vol. 11(11): 1006-1012 — demonstrated cognitive reserve protects cognition despite neuropathology.

Immune aging (immunosenescence): The thymus involutes (shrinks), producing fewer T cells. B cell function declines. The immune system simultaneously becomes more prone to inflammation (inflammaging) while being less effective at fighting infections and cancer. This explains why older people suffer more from flu and pneumonia yet also have higher cancer rates — the immune system is simultaneously weak and overactive. Vaccine response declines, though studies show that exercise, adequate sleep, and specific micronutrients (zinc, vitamin D) preserve immune function better than in sedentary, sleep-deprived elders.

Cardiovascular aging: Arterial stiffness increases due to collagen cross-linking and calcification (vascular aging). Heart contractility declines slightly. Blood pressure creep is nearly universal with age. However, ~10% of 80-year-olds have "supernormal" cardiovascular aging — arterial stiffness no worse than 30-year-olds. Aerobic exercise is the single most powerful intervention for preserving cardiovascular youth, with regular runners showing 20-30 year younger arteries than sedentary peers.

Muscle aging (sarcopenia): Muscle mass declines ~0.5% per year after age 30 (faster after 60). This is driven by motor neuron loss, declining protein synthesis, mitochondrial dysfunction, and reduced growth hormone. However, resistance training can reverse sarcopenia — elderly people starting strength training can regain muscle mass in weeks to months. This is one of the most modifiable hallmarks of aging.

Lifespan Records and Transgenic Models

Longest-lived humans: Jeanne Calment (1997, 122 years 164 days) remains the verified record. The next oldest verified person died in 2023 at 119. Supercentenarian records beyond ~120 years are disputed — Saul Newman's 2024 analysis showed that many records worldwide (Methuselah Foundation, various countries) likely result from record fraud or age confusion. Verified centenarians cluster in specific countries with excellent record-keeping (Japan, Sardinia, Italy), suggesting record quality matters.

Longest-lived transgenic mice: The record is held by a mouse with reduced growth hormone signaling (hypopituitary dwarf mouse), living ~4-5 years (vs. 2-3 years for wild-type). This animal was also infertile, raising questions about trade-offs. Caloric-restricted mice, rapamycin-treated mice, and certain genetic knockouts (IGF-1R, mTOR, p66ShcA) all consistently extend lifespan 20-40% in mice. Whether these translate to humans is the fundamental challenge of aging research.

Methuselah's record holders: The longest-lived organisms are:

• Bristlecone pines: ~5,000 years (Methuselah, confirmed; possibly older unnamed specimens)
• Quahog clams: ~500+ years
• Greenland sharks: ~400+ years (estimated; hard to verify)
• Hydra: negligible senescence (timeless)
• Turritopsis dohrnii (immortal jellyfish): potentially infinite (via transdifferentiation)

These demonstrate that aging is not immutable. The mechanisms differ — bristlecone pines grow very slowly and have exceptional DNA repair; Hydra continuously replace cells; jellyfish revert to larval stage. These model organisms are expanding our understanding of what's possible biologically.

Genetic Architecture of Longevity

Twin studies show that lifespan heritability is roughly 25-35% — genes matter, but less than environment and lifestyle. The genetic factors identified so far:

FOXO family (Forkhead transcription factors): Regulate stress resistance, DNA repair, and autophagy. Loss-of-function mutations in daf-16 (FOXO homolog) in C. elegans eliminates lifespan extension from caloric restriction and reduced IGF-1 signaling. Human FOXO variants associate with longevity in some populations.

Sirtuins (NAD+-dependent deacetylases): Seven mammalian sirtuins (SIRT1-7) regulate aging processes. SIRT1 and SIRT3 overexpression extends lifespan in mice. Resveratrol and other compounds activate sirtuins, though whether they extend human lifespan is unclear. NAD+ boosters (NMN, NR) work partly through sirtuin activation.

AMPK (AMP-activated protein kinase): The "metabolic master switch," activated by exercise and caloric restriction. AMPK activators (metformin, direct AMPK activators in development) extend lifespan in mice, possibly by improving mitochondrial function and autophagy.

mTOR pathway: High mTOR activity (common in overeating and obesity) accelerates aging. mTOR inhibition (rapamycin) extends lifespan dramatically in mice. However, mTOR is also required for muscle growth, explaining why some rapamycin users develop muscle weakness.

Genome-wide association studies (GWAS) in centenarian populations have identified variants in genes related to cholesterol metabolism (APOE, CETP), stress response (FOXO3), and DNA repair. However, no single genetic variant is strongly predictive of human longevity — it's polygenic and environment-dependent.

Source: Sebastiani, P., et al. (2012) "Genetic Signatures of Exceptional Longevity in Humans," PLOS ONE, Vol. 7(12). — GWAS of 1,600+ centenarians identifying candidate longevity variants.

Recent Advances and 2026 Outlook

Senolytic trials expanding: Beyond fisetin, trials of navitoclax (ABT-263) for pulmonary fibrosis, arthritis, and frailty are recruiting. Combination senolytics are showing synergistic effects in mice.

Partial reprogramming in large animals: 2024 saw reports of cyclic Yamanaka factor expression in aged dogs showing reversal of biological aging markers and improvement in mobility in some dogs. This is the first large-animal demonstration, raising hopes for primate/human trials.

Microbiome targeting: Young microbiota transplantation and engineered probiotics (e.g., Akkermansia muciniphila supplementation) extended lifespan and healthspan in aged mice. Human trials are beginning in cognitively normal elders to assess efficacy for brain aging.

Combination therapies: The field is moving toward cocktails — e.g., rapamycin + senolytics + metformin, each targeting different hallmarks. Mouse studies show synergy; human trials are years away.

The Takeaway

Aging isn't a mystery — it's a collection of broken cellular systems that can, in principle, be fixed. The 12 hallmarks give us a map. Senolytics, caloric restriction, and reprogramming show that aging is malleable — not an immutable law of nature but a tractable engineering problem. We're not at reversing aging yet, but we're no longer stuck asking "why must we age?" The question now is "which hallmarks should we fix first?" For most people, the best near-term answer remains: exercise, sleep, Mediterranean diet, no smoking. For researchers, the frontier is senolytics, reprogramming, and combination therapies now entering clinical trials.

---

Read next:

• Epigenetics Explained — How Environment Changes Your DNA
• How the Immune System Actually Works
• Mitochondria Explained — The Powerhouse of the Cell